

WHO Technical Consultation to review the Manual on *Plasmodium vivax* case management

8 - 10 October 2024, Crowne Plaza, Geneva, Switzerland

Agenda time zone: Central European Time (CET)

DRAFT AGENDA

Chairperson: tbd

Rapporteur: Naomi Richardson

Agenda overview and meeting objectives Ools New WHO recommendations on tafenoquine, primaquine, G6PD testing (20' presentation + 5' discussion) Development of manual and overview about structure and content (20' presentation + 10' discussion) Coffee break Country experiences / study findings (TQ, PQ, G6PD testing, ARCTIC, SCOPE, TRUST, etc) Country A, B, C (10' each) Study 1,2,3 (10' each) Plenary discussion (30')	Daniel Ngamije Silvia Schwarte Tbd (AB, PO) Tbd (Consultant/Writer) Tbd (Country representatives, PAVE: MMV, PATH,) Plenary
New WHO recommendations on tafenoquine, primaquine, G6PD testing (20' presentation + 5' discussion) Development of manual and overview about structure and content (20' presentation + 10' discussion) Coffee break Country experiences / study findings (TQ, PQ, G6PD testing, ARCTIC, SCOPE, TRUST, etc) Country A, B, C (10' each) Study 1,2,3 (10' each)	Tbd (AB, PO) Tbd (Consultant/Writer) Tbd (Country representatives, PAVE: MMV, PATH,)
GGPD testing (20' presentation + 5' discussion) Development of manual and overview about structure and content (20' presentation + 10' discussion) Coffee break Country experiences / study findings (TQ, PQ, G6PD testing, ARCTIC, SCOPE, TRUST, etc) Country A, B, C (10' each) Study 1,2,3 (10' each)	(AB, PO) Tbd (Consultant/Writer) Tbd (Country representatives, PAVE: MMV, PATH,)
Content (20' presentation + 10' discussion) Coffee break Country experiences / study findings (TQ, PQ, G6PD testing, ARCTIC, SCOPE, TRUST, etc) Country A, B, C (10' each) Study 1,2,3 (10' each)	Tbd (Country representatives, PAVE: MMV, PATH,)
Country experiences / study findings (TQ, PQ, G6PD testing, ARCTIC, SCOPE, TRUST, etc) Country A, B, C (10' each) Study 1,2,3 (10' each)	(Country representatives, PAVE: MMV, PATH,)
ARCTIC, SCOPE, TRUST, etc) Country A, B, C (10' each) Study 1,2,3 (10' each)	(Country representatives, PAVE: MMV, PATH,)
Lunch break	
Chapter 1 – (Introduction) Presentation of primary reviewers' comments on gaps and areas for strengthening (15') Plenary discussion (60')	Primary Reviewers Plenary
Chapter 2 – (WHO recommendations, 2024 update) Presentation of primary reviewers' comments on gaps and areas for strengthening (30') Plenary discussion (60')	Primary Reviewers Plenary
Coffee break	
Chapter 3 – (Plasmodium vivax case management) Presentation of primary reviewers' comments on gaps and areas For strengthening (30') Plenary discussion (60')	Primary Reviewers Plenary
	resentation of primary reviewers' comments on gaps and areas or strengthening (15') lenary discussion (60') chapter 2 – (WHO recommendations, 2024 update) resentation of primary reviewers' comments on gaps and areas or strengthening (30') lenary discussion (60') coffee break chapter 3 – (Plasmodium vivax case management) resentation of primary reviewers' comments on gaps and areas or strengthening (30')

Wednesday, 9 October 2024			
09:00 – 09:10	Recap Day 1	Chairperson / Consultant/Writer	
09:10 – 10:40	Chapter 4 – (Planning) Presentation of primary reviewers' comments on gaps and areas for strengthening (30') Plenary discussion (60')	Primary Reviewers Plenary	
10:40 – 10:55	Coffee break		
10:55 – 12:25	Chapter 5 – (Implementation) Presentation of primary reviewers' comments on gaps and areas for strengthening (30')	Primary Reviewers	
	Plenary discussion (60')	Plenary	
12:25 – 13:30	Lunch break		
13:30 – 15:00	Chapter 6 – (M&E) Presentation of primary reviewers' comments on gaps and areas for strengthening (30')	Primary Reviewers	
	Plenary discussion (60')	Plenary	
15:00 – 15:45	Chapter 7 – (references, usefuld further reading, annexes, etc) Presentation of primary reviewers' comments on gaps and areas for strengthening (30') Plenary discussion (60')	Primary Reviewers Plenary	
15:45 – 16:00	Coffee break		
16:00 – 16:45	Chapter 7 – Plenary discussion continued	Plenary	
	End of Day		

Thursday, 10 October 2024			
09:00 – 09:10	Recap Day 2	Chairperson / Consultant/Writer	
09:10 – 11:00	Plenary discussion on the manual and pending items Plenary discussion (110')	Naomi Richardson / Chair / Primary Reviewers / Plenary	
11:00 – 11:15	Coffee break		
11:15 – 11:30	Next steps, finalization, and dissemination plans	Silvia Schwarte	
11:30 – 12:00	Closing remarks	Daniel Ngamije	
	End of Meeting		